Hansa Biopharma — November 2022
-
Gentager lige SEB's "Buy Target price: SEK 260" tilbage fra oktober 22 inkl. deres kommentar vedr. AMR.
"AMR is major potential trigger in latter half of Q4. "We forecast a potential peak sales opportunity of SEK 21bn in 2034, with a potential 2026 launch."
-
-
tror også at meldingerne om 2034, +- 50% på peak sales, fair share af salget, dermed de store udsving i target price.. alt samnen betyder at aktien ikke er så interessant for de fleste. Jeg har den i rigelige mængder og der ligger den… om det så ender med kurs 200 eller kurs 600.. its a bet, men lille chance for ikke at få en gevinst.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

